GT BIOPHARMA, INC. Increase Decrease In Operating Lease Liability
GT BIOPHARMA, INC. (GTBP) reported Increase Decrease In Operating Lease Liability of -$58.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-03-06
- GT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2024-12-31 was $0.00.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was $0.00.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$30.00K.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$28.00K.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2024 was -$58.00K.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2023 was -$116.00K.
- GT BIOPHARMA, INC. increase decrease in operating lease liability for fiscal 2022 was -$86.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | -$30.00K derived: sum of 3 quarters · filed 2026-03-06 | -$58.00K 10-K · filed 2026-03-02 |
| 2024-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2026-03-06 | -$30.00K derived: sum of 2 quarters · filed 2026-03-06 | -$58.00K 10-Q/A · filed 2026-03-06 | -$92.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$58.00K 10-Q · filed 2024-08-14 | -$92.00K derived: sum of 3 quarters · filed 2025-02-21 | -$120.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2024-03-31 | -$28.00K 10-Q · filed 2024-05-15 | -$62.00K derived: sum of 2 quarters · filed 2025-02-21 | -$90.00K derived: sum of 3 quarters · filed 2025-02-21 | -$117.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-12-31 | -$34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$62.00K derived: sum of 2 quarters · filed 2025-02-21 | -$89.00K derived: sum of 3 quarters · filed 2025-02-21 | -$116.00K 10-K · filed 2025-02-21 |
| 2023-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$55.00K derived: sum of 2 quarters · filed 2024-11-14 | -$82.00K 10-Q · filed 2024-11-14 | -$106.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$54.00K 10-Q · filed 2024-08-14 | -$78.00K derived: sum of 3 quarters · filed 2024-08-14 | -$103.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$27.00K 10-Q · filed 2024-05-15 | -$51.00K derived: sum of 2 quarters · filed 2024-05-15 | -$76.00K derived: sum of 3 quarters · filed 2024-05-15 | -$100.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$49.00K derived: sum of 2 quarters · filed 2024-03-26 | -$73.00K derived: sum of 3 quarters · filed 2024-03-26 | -$86.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | -$25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$49.00K derived: sum of 2 quarters · filed 2023-11-01 | -$62.00K 10-Q · filed 2023-11-01 | |
| 2022-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$37.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$13.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |